The authors of this study have previously described their experience with the use of infliximab in 9 children with moderate to severe ulcerative colitis (UC).
In this study, they assessed the outcome of these patients after a minimum 2-year follow-up. They also described the responses of 8 additional patients.
The team reviewed all pediatric patients with UC who received infliximab at the Children's Hospital of Philadelphia from its first use until February 2003.
The team recorded the patients' tolerance to the infusions and the occurrence of any adverse events.
|Infliximab was well tolerated.|
|Journal of Pediatric Gastroenterology and Nurtition|
The doctor's reviewed follow-up information for the 9 initial patients.
The team found that these patients received a total of 73 infliximab infusions. They found that 78% were responders to the initial dose of infliximab.
However, 2 patients became nonresponders within 9 months of the first dose and underwent colectomy.
The doctors determined that 88% of the additional patients were responders. However, 1 responder relapsed within 2 months.
Overall, the team observed a short-term improvement 82% of patients. They found sustained improvement in 63% of those followed for more than 9 months.
Dr Petar Mamula's team concluded, "Infliximab is associated with short- and long-term clinical improvement in children and adolescents with moderate to severe UC."